Thoracic Cancer (May 2021)

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

  • Seiichiro Kusuhara,
  • Satoshi Igawa,
  • Masaaki Ichinoe,
  • Ryo Nagashio,
  • Yuki Kuchitsu,
  • Yasuhiro Hiyoshi,
  • Kazu Shiomi,
  • Yoshiki Murakumo,
  • Makoto Saegusa,
  • Yukitoshi Satoh,
  • Yuichi Sato,
  • Katsuhiko Naoki

DOI
https://doi.org/10.1111/1759-7714.13945
Journal volume & issue
Vol. 12, no. 10
pp. 1570 – 1578

Abstract

Read online

Abstract Background Galectin‐3 (GAL3), a protein encoded by the LGALS3 gene, plays diverse roles in cancer initiation, progression, and drug resistance. Accordingly, high GAL3 expression in tumor cells is associated with poor prognosis in non‐small cell lung cancer (NSCLC). However, the prognostic impact of GAL3 expression on patients with resected NSCLC receiving platinum‐based adjuvant chemotherapy (AC) remains unclear. This study aimed to determine the prognostic significance of GAL3 expression in NSCLC patients receiving platinum‐based AC. Methods The study included 111 patients with completely resected stages II and IIIA NSCLC who were receiving platinum‐based AC. GAL3 expression in cancer cells was evaluated immunohistochemically according to H‐score (“histo score), with a score of ≥170 considered as high expression. The correlation of GAL3 expression with clinicopathological characteristics and survival was subsequently evaluated. Results In survival analysis, GAL3 expression was significantly associated with recurrence‐free survival (RFS) and overall survival (OS). In multivariate analysis, GAL3 expression was an independent predictive factor of RFS rather than OS. Conclusions GAL3 expression is a reliable biomarker to predict the prognosis of completely resected NSCLC patients receiving platinum‐based AC.

Keywords